Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin

Annals of Oncology

Volumn 21, Issue 4, 2009, Pages 772-780

  Zaanan, A ^a,b,c   Cuilliere Dartigues, P ^a,b,c   Guilloux, A ^a,b   Parc, Y ^a,b,c   Louvet, C ^a,b,c   de Gramont, A ^a,b,c   Tiret, E ^b,c   Dumont, S ^b   Gayet, B ^d   Validire, P ^e   Flejou J F ^a,b,c   Duval, A ^a,b   Praz, F ^a,b  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e INSTITUT MUTUALISTE MONTSOURIS   (France)

Author keywords

Chemotherapy; Colon cancer; Disease free survival; Microsatellite instability; Oxaliplatin; p53

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; COLON RESECTION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MULTIPLE CYCLE TREATMENT; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 77951967408     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp383     Document Type: Article

References (43)

1. Moertel CG, Fleming TR, Macdonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322(6): 352-358.
2. O'Connell MJ, Laurie JA, Kahn M et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16(1): 295-300.
3. Andre T, Colin P, Louvet C et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003; 21(15): 2896-2903.
4. Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350(23): 2343-2351.
5. Kuebler JP, Wieand HS, O'Connell MJ et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25(16): 2198-2204.
6. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997; 386(6625): 623-627.
7. Samowitz WS, Holden JA, Curtin K et al. Inverse relationship between microsatellite instability and K-ras and p53 gene alterations in colon cancer. Am J Pathol 2001; 158(4): 1517-1524.
8. Kim GP, Colangelo LH, Wieand HS et al. Prognostic and predictive roles of highdegree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2007; 25(7): 767-772.
9. Iacopetta B. TP53 mutation in colorectal cancer. Hum Mutat 2003; 21(3): 271-276.
10. Iacopetta B, Russo A, Bazan V et al. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Ann Oncol 2006; 17(5): 842-847.
11. Kressner U, Inganas M, Byding S et al. Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol 1999; 17(2): 593-599.
12. Soong R, Robbins PD, Dix BR et al. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 1996; 27(10): 1050-1055.
13. Elsaleh H, Joseph D, Grieu F et al. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000; 355(9217): 1745-1750.
14. Gryfe R, Kim H, Hsieh ET et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000; 342(2): 69-77.
15. Hemminki A, Mecklin JP, Jarvinen H et al. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000; 119(4): 921-928.
16. Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349(3): 247-257.
17. Carethers JM, Smith EJ, Behling CA et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004; 126(2): 394-401.
18. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23(3): 609-618.
19. Sinicrope FA, Rego RL, Halling KC et al. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology 2006; 131(3): 729-737.
20. Tortola S, Marcuello E, Gonzalez I et al. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. J Clin Oncol 1999; 17(5): 1375-1381.
21. Tang R, Wang JY, Fan CW et al. p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy. Cancer Lett 2004; 210(1): 101-109.
22. Allegra CJ, Paik S, Colangelo LH et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2003; 21(2): 241-250.
23. Gallego MG, Acenero MJ, Ortega S et al. Prognostic influence of p53 nuclear overexpression in colorectal carcinoma. Dis Colon Rectum 2000; 43(7): 971-975.
24. Garrity MM, Burgart LJ, Mahoney MR et al. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol 2004; 22(9): 1572-1582.
25. Popat S, Chen Z, Zhao D et al. A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. Ann Oncol 2006; 17(12): 1810-1817.
26. de Gramont A, Louvet C, Andre T et al. A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). Eur J Cancer 1998; 34(5): 619-626.
27. Jourdan F, Sebbagh N, Comperat E et al. Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. Virchows Arch 2003; 443(2): 115-121.
28. Baas IO, Mulder JW, Offerhaus GJ et al. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994; 172(1): 5-12.
29. Rashid A, Zahurak M, Goodman SN, Hamilton SR. Genetic epidemiology of mutated K-ras proto-oncogene, altered suppressor genes, and microsatellite instability in colorectal adenomas. Gut 1999; 44(6): 826-833.
30. Samowitz WS, Curtin K, Ma KN et al. Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer 2002; 99(4): 597-602.
31. Grambsch PM. Goodness-of-fit and diagnostics for proportional hazards regression models. Cancer Treat Res 1995; 75: 95-112.
32. Berger AC, Sigurdson ER, LeVoyer T et al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 2005; 23(34): 8706-8712.
33. Lee HY, Choi HJ, Park KJ et al. Prognostic significance of metastatic lymph node ratio in node-positive colon carcinoma. Ann Surg Oncol 2007; 14(5): 1712-1717.
34. Sargent DJ, Wieand HS, Haller DG et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005; 23(34): 8664-8670.
35. des Guetz G, Mariani P, Cucherousset J et al. Microsatellite instability and sensitivity to FOLFOX treatment in metastatic colorectal cancer. Anticancer Res 2007; 27(4C): 2715-2719.
36. Muller CI, Schulmann K, Reinacher-Schick A et al. Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group. Int J Colorectal Dis 2008; 23(11): 1033-1039.
37. Fink D, Nebel S, Aebi S et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996; 56(21): 4881-4886.
38. Vaisman A, Varchenko M, Umar A et al. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 1998; 58(16): 3579-3585.
39. Miquel C, Jacob S, Grandjouan S et al. Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability. Oncogene 2007; 26(40): 5919-5926.
40. Loire E, Praz F, Higuet D et al. Hypermutability of genes in Homo sapiens due to the hosting of long mono-SSR. Mol Biol Evol 2009; 26(1): 111-121.
41. Boyer J, McLean EG, Aroori S et al. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res 2004; 10(6): 2158-2167.
42. McDermott U, Longley DB, Galligan L et al. Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer. Cancer Res 2005; 65(19): 8951-8960.
43. Toscano F, Parmentier B, Fajoui ZE et al. p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells. Biochem Pharmacol 2007; 74(3): 392-406.